Experienced biotech entrepreneur with strong expertise in strategy, innovation, and fundraising. He has led teams that advanced four drug candidates from research to clinical development (up to Phase IIb) and has raised over €170 million from international investors and strategic partners.
He is currently Managing Director of CarKath, a strategic consulting firm, and serves on several boards, including as Chairman of ErVimmune, Ergosuture, and Biosenic.
Previously, he was CEO of PDC*line Pharma for nearly 10 years and CEO of Promethera Biosciences/Cellaïon for 6 years, contributing to multiple biotech M&A transactions and IPOs. He is also co-inventor of a GMP-approved mobile manufacturing unit for cell therapy.
Earlier in his career, he spent 12 years at Arthur D. Little leading international strategy and innovation projects for pharmaceutical and biotech companies.
He has co-founded several biotech ventures, including Myosix (acquired by Genzyme), Murigenetics, Digital Orthopaedics, and HairClone.
